Endra Life Sciences Inc. (NDRA) Stock Price & Analysis
Endra Life Sciences Inc. (NDRA) rose 6.51% to USD 6.05 as of September 8, 2026 at 08:21 UTC, according to Nexqual real-time market data.
NDRA last closed at USD 6.05; the session ranged USD 5.7–6.37 on volume of 20,582 shares. Market capitalization is —, with a 52-week range of USD 2.96–9.85 (NCM). Source: Nexqual, September 8, 2026 at 08:21 UTC.
Key Statistics (as of September 8, 2026 at 08:21 UTC)
| Price | USD 6.05 |
|---|---|
| Change | ▲ 6.51% (up) |
| Previous Close | USD 6.05 |
| Open | USD 6.05 |
| Day Range | USD 5.7 – 6.37 |
| 52-Week Range | USD 2.96 – 9.85 |
| Volume | 20,582 shares |
| Market Cap | — |
| Exchange | NCM |
Technical Analysis (NDRA)
Nexqual's technical model rates NDRA "STRONG BUY" based on 5 bullish and 0 bearish signals across 128 daily candles, as of September 8, 2026 at 08:21 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 61.44 (neutral) |
| vs SMA50 | Above (USD 4.94) |
| MACD | 0.29 (positive) |
From Endra Life Sciences Inc.'s Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- The collection and use of health data and other personal data including data collected in clinical trials is governed in the EU by the General Data Protection Regulation ("GDPR"), which imposes substantial obligations upon companies and new rights for individuals.
- Before and after approval, grant or clearance in the United States, our applications are subject to extensive regulation by the FDA under the Federal Food, Drug and Cosmetic Act (the "FD&C Act") and/or the Public Health Service Act, as well as by other regulatory bodies.
- We also enter into nondisclosure agreements with our commercial counterparties and limit access to, and distribution of, our proprietary information.   We are committed to developing and protecting our intellectual property and, where appropriate, filing patent applications to protect our technology.
- These waves are then detected with ultrasound sensors at the skin surface and used to create high-contrast images (and other forms of data) using our proprietary algorithms.
Partnerships
- In connection with its DAT strategy, Company entered into a Master Custody Service Agreement with Anchorage (the "Custody Agreement"), pursuant to which it will act as custodian of the Company's digital assets it deposits with Anchorage.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| DARE | Dare Bioscience, Inc. | USD 0.72 | ▼ 2.57% |
| MOTS | Motus GI Holdings, Inc. | USD 0 | ▲ 100% |
| MBIO | Mustang Bio, Inc. | USD 0.54 | ▼ 0.02% |
| MBAI | MBody AI Ltd. | USD 6.5 | ▲ 0.31% |
| DCOY | Decoy Therapeutics Inc. | USD 2.69 | ▼ 9.73% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: September 8, 2026 at 08:21 UTC. This page is informational and not investment advice.